Új immunterápiás lehetõségek az emlõrák kezelésében

Translated title of the contribution: Immunotherapy opportunities in breast cancer

Lajos Pusztai, A. Ladányi, Borbála Székely, Magdolna Dank

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The prognostic value of tumor infiltrating lymphocytes in breast cancer has long been recognized by histopathologists. These observations were reaffirmed by recent immunohistochemistry and gene expression profiling studies that also revealed an association between greater chemotherapy sensitivity and extensive lymphocytic infiltration in early stage breast cancers treated with neoadjuvant chemotherapy. These results suggest that local anti-tumor immune response can at least partially control cancer growth and may mediate the antitumor effects of chemotherapy. However, until recently, there was no direct clinical evidence to demonstrate that enhancing anti-tumor immune response could lead to clinical benefit in breast cancer patients. The recent development of clinically effective immune checkpoint inhibitors made it possible to test the therapeutic impact of augmenting the local anti-tumor immune response. Two Phase I clinical trials using single agent anti-PD-1 (MK-3475, pembrolizumab) and anti-PD-L1 (MPDL3280A, atezolizumab) antibodies demonstrated close to 20% tumor response rates in heavily pretreated, metastatic, triple negative breast cancers. The most remarkable feature of the responses was their long duration. Several patients had disease control close to a year, or longer, which has not previously been seen with chemotherapy regimens in this patient population. A large number of clinical trials are currently underway with these and similar drugs in the neoadjuvant, adjuvant and metastatic settings to define the role of this new treatment modality in breast cancer.

Original languageHungarian
Pages (from-to)34-40
Number of pages7
JournalMagyar Onkologia
Volume60
Issue number1
Publication statusPublished - Mar 2 2016

Fingerprint

Immunotherapy
Breast Neoplasms
Drug Therapy
Neoplasms
Triple Negative Breast Neoplasms
Tumor-Infiltrating Lymphocytes
Clinical Trials, Phase I
Gene Expression Profiling
Immunohistochemistry
Clinical Trials
Antibodies
Therapeutics
Growth
Pharmaceutical Preparations
Population
pembrolizumab
MPDL3280A

ASJC Scopus subject areas

  • Oncology

Cite this

Pusztai, L., Ladányi, A., Székely, B., & Dank, M. (2016). Új immunterápiás lehetõségek az emlõrák kezelésében. Magyar Onkologia, 60(1), 34-40.

Új immunterápiás lehetõségek az emlõrák kezelésében. / Pusztai, Lajos; Ladányi, A.; Székely, Borbála; Dank, Magdolna.

In: Magyar Onkologia, Vol. 60, No. 1, 02.03.2016, p. 34-40.

Research output: Contribution to journalReview article

Pusztai, L, Ladányi, A, Székely, B & Dank, M 2016, 'Új immunterápiás lehetõségek az emlõrák kezelésében', Magyar Onkologia, vol. 60, no. 1, pp. 34-40.
Pusztai, Lajos ; Ladányi, A. ; Székely, Borbála ; Dank, Magdolna. / Új immunterápiás lehetõségek az emlõrák kezelésében. In: Magyar Onkologia. 2016 ; Vol. 60, No. 1. pp. 34-40.
@article{56560e33415f45ebaeb9a5adbe1ea8f8,
title = "{\'U}j immunter{\'a}pi{\'a}s lehet{\~o}s{\'e}gek az eml{\~o}r{\'a}k kezel{\'e}s{\'e}ben",
abstract = "The prognostic value of tumor infiltrating lymphocytes in breast cancer has long been recognized by histopathologists. These observations were reaffirmed by recent immunohistochemistry and gene expression profiling studies that also revealed an association between greater chemotherapy sensitivity and extensive lymphocytic infiltration in early stage breast cancers treated with neoadjuvant chemotherapy. These results suggest that local anti-tumor immune response can at least partially control cancer growth and may mediate the antitumor effects of chemotherapy. However, until recently, there was no direct clinical evidence to demonstrate that enhancing anti-tumor immune response could lead to clinical benefit in breast cancer patients. The recent development of clinically effective immune checkpoint inhibitors made it possible to test the therapeutic impact of augmenting the local anti-tumor immune response. Two Phase I clinical trials using single agent anti-PD-1 (MK-3475, pembrolizumab) and anti-PD-L1 (MPDL3280A, atezolizumab) antibodies demonstrated close to 20{\%} tumor response rates in heavily pretreated, metastatic, triple negative breast cancers. The most remarkable feature of the responses was their long duration. Several patients had disease control close to a year, or longer, which has not previously been seen with chemotherapy regimens in this patient population. A large number of clinical trials are currently underway with these and similar drugs in the neoadjuvant, adjuvant and metastatic settings to define the role of this new treatment modality in breast cancer.",
author = "Lajos Pusztai and A. Lad{\'a}nyi and Borb{\'a}la Sz{\'e}kely and Magdolna Dank",
year = "2016",
month = "3",
day = "2",
language = "Hungarian",
volume = "60",
pages = "34--40",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Új immunterápiás lehetõségek az emlõrák kezelésében

AU - Pusztai, Lajos

AU - Ladányi, A.

AU - Székely, Borbála

AU - Dank, Magdolna

PY - 2016/3/2

Y1 - 2016/3/2

N2 - The prognostic value of tumor infiltrating lymphocytes in breast cancer has long been recognized by histopathologists. These observations were reaffirmed by recent immunohistochemistry and gene expression profiling studies that also revealed an association between greater chemotherapy sensitivity and extensive lymphocytic infiltration in early stage breast cancers treated with neoadjuvant chemotherapy. These results suggest that local anti-tumor immune response can at least partially control cancer growth and may mediate the antitumor effects of chemotherapy. However, until recently, there was no direct clinical evidence to demonstrate that enhancing anti-tumor immune response could lead to clinical benefit in breast cancer patients. The recent development of clinically effective immune checkpoint inhibitors made it possible to test the therapeutic impact of augmenting the local anti-tumor immune response. Two Phase I clinical trials using single agent anti-PD-1 (MK-3475, pembrolizumab) and anti-PD-L1 (MPDL3280A, atezolizumab) antibodies demonstrated close to 20% tumor response rates in heavily pretreated, metastatic, triple negative breast cancers. The most remarkable feature of the responses was their long duration. Several patients had disease control close to a year, or longer, which has not previously been seen with chemotherapy regimens in this patient population. A large number of clinical trials are currently underway with these and similar drugs in the neoadjuvant, adjuvant and metastatic settings to define the role of this new treatment modality in breast cancer.

AB - The prognostic value of tumor infiltrating lymphocytes in breast cancer has long been recognized by histopathologists. These observations were reaffirmed by recent immunohistochemistry and gene expression profiling studies that also revealed an association between greater chemotherapy sensitivity and extensive lymphocytic infiltration in early stage breast cancers treated with neoadjuvant chemotherapy. These results suggest that local anti-tumor immune response can at least partially control cancer growth and may mediate the antitumor effects of chemotherapy. However, until recently, there was no direct clinical evidence to demonstrate that enhancing anti-tumor immune response could lead to clinical benefit in breast cancer patients. The recent development of clinically effective immune checkpoint inhibitors made it possible to test the therapeutic impact of augmenting the local anti-tumor immune response. Two Phase I clinical trials using single agent anti-PD-1 (MK-3475, pembrolizumab) and anti-PD-L1 (MPDL3280A, atezolizumab) antibodies demonstrated close to 20% tumor response rates in heavily pretreated, metastatic, triple negative breast cancers. The most remarkable feature of the responses was their long duration. Several patients had disease control close to a year, or longer, which has not previously been seen with chemotherapy regimens in this patient population. A large number of clinical trials are currently underway with these and similar drugs in the neoadjuvant, adjuvant and metastatic settings to define the role of this new treatment modality in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85012072078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012072078&partnerID=8YFLogxK

M3 - Review article

C2 - 26934349

AN - SCOPUS:85012072078

VL - 60

SP - 34

EP - 40

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -